Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNP023 versus rituximab in idiopathic membranous nephropathy
2019-001734-34Phase 2Unknown
- Sponsor
- Novartis
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Iptacopan and rituximab in idiopathic membranous glomerulonephritis (IMG) (3 arms), sponsored by Novartis. Primary endpoint: Ratio between baseline UPCR and UPCR at 24 weeks of treatment. Status: unknown.
02
Drugs
Iptacopanrituximab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on 2019-001734-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001734-34.